Claire Padgett

431 total citations
11 papers, 294 citations indexed

About

Claire Padgett is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claire Padgett has authored 11 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claire Padgett's work include Click Chemistry and Applications (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and HER2/EGFR in Cancer Research (2 papers). Claire Padgett is often cited by papers focused on Click Chemistry and Applications (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and HER2/EGFR in Cancer Research (2 papers). Claire Padgett collaborates with scholars based in United States, Germany and United Kingdom. Claire Padgett's co-authors include R. A. Buchanan, Sean O’Brien, Gregory M. Kochak, John G. Page, Joan Perelló, Alex Gold, Glenn M. Chertow, Smeeta Sinha, Markus Ketteler and Carolina Salcedo and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Claire Padgett

9 papers receiving 291 citations

Peers

Claire Padgett

NEPHR

ONCOL

PMH

PRM

Ali Baker United Kingdom

Andrew Y. Shuen Canada

Bozena Krolewski United States

Yehani Wedatilake United Kingdom

Trude Skogstrand Norway

Gabin Sihn Germany

Soledad Kleppe United States

Yanli Yan China

Victoria McEneaney Ireland

Isabelle Redonnet‐Vernhet France

Ali Baker United Kingdom

Claire Padgett

150 ×1.6

140 ×1.7

NEPHR

28 ×0.4

ONCOL

17 ×0.4

PMH

31 ×0.7

PRM

Citations per year, relative to Claire Padgett Claire Padgett (= 1×) peers Ali Baker

Countries citing papers authored by Claire Padgett

Since Specialization

Citations

This map shows the geographic impact of Claire Padgett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Padgett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Padgett more than expected).

Fields of papers citing papers by Claire Padgett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Padgett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Padgett. The network helps show where Claire Padgett may publish in the future.

Co-authorship network of co-authors of Claire Padgett

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Padgett. A scholar is included among the top collaborators of Claire Padgett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Padgett. Claire Padgett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Yu, Alan S.L., Keith Bellovich, Claire Padgett, et al.. (2024). RGLS8429 Increases Urinary PC1 and PC2 and May Reduce Height-Adjusted Total Kidney Volume (htTKV) in Patients with ADPKD. Journal of the American Society of Nephrology. 35(10S).

Sinha, Smeeta, Lisa J. Gould, Sagar U. Nigwekar, et al.. (2021). The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clinical Kidney Journal. 15(1). 136–144. 19 indexed citations

Raggi, Paolo, Antonio Bellasi, David A. Bushinsky, et al.. (2019). Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. Circulation. 141(9). 728–739. 104 indexed citations

Drygin, Denis, Caroline B. Ho, Mayuko Omori, et al.. (2011). Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and Biophysical Research Communications. 415(1). 163–167. 57 indexed citations

Marschke, Robert F., Mitesh J. Borad, Robert McFarland, et al.. (2011). Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.. Journal of Clinical Oncology. 29(15_suppl). 3087–3087. 37 indexed citations

Padgett, Claire, Robert F. Marschke, Eleni Andreopoulou, et al.. (2010). 414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial. European Journal of Cancer Supplements. 8(7). 131–132. 13 indexed citations

Lim, John K. C., Claire Padgett, Robert F. Marschke, et al.. (2010). Abstract 2763: Utility of clinical biomarkers for detecting protein kinase CK2 inhibition: A report from the phase I trial of CX-4945. Cancer Research. 70(8_Supplement). 2763–2763.

Marschke, Robert F., Eleni Andreopoulou, Daniel D. Von Hoff, et al.. (2009). Abstract C39: Phase I clinical trial of CX-4945: A first-in-class orally administered small molecule inhibitor of protein kinase CK2. Molecular Cancer Therapeutics. 8(12_Supplement). C39–C39. 1 indexed citations

Fitch, Tom R., Donald W. Northfelt, Pamela P. Griffin, et al.. (2008). Phase I clinical trial of quarfloxin administered weekly×3 of a four week cycle. Journal of Clinical Oncology. 26(15_suppl). 14667–14667. 3 indexed citations

10.

Papadopoulos, Kyriakos P., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 10 indexed citations

11.

Kochak, Gregory M., et al.. (1998). Steady‐State Pharmacokinetics of Zonisamide, an Antiepileptic Agent for Treatment of Refractory Complex Partial Seizures. The Journal of Clinical Pharmacology. 38(2). 166–171. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact